Lior Carmon, Ph.D., MBA
Founder CEO
and head of research
Dr. Carmon is an expert in the fields of immunology and cancer with an in depth understanding of the science, business and market trends of cancer Immunotherapy. For the last 15 years, Dr. Carmon has served as a manager and founder in several Israeli biotech companies including as General Manager at Ester Neurosciences Ltd (acquired by Amarin Corp.), and as founder and VP business Development at CureTech Ltd. and at BioKine Therapeutics Ltd., two companies in the field of immune modulation and immunotherapy. Prior thereto Dr. Carmon was VP of technology Assessment and Strategic Alliances at Clal Biotechnology Industries (CBI), Israel’s largest life sciences investment fund. Dr. Carmon currently serves as a board member of the Israeli immunology society (IIS). He received his Ph.D. in tumor Immunology from the Weizmann Institute and his MBA from the school of management Ben-Gurion University, Israel.

Julian Levy M.A.
President and CFO

Julian Levy is a biotech entrepreneur with particular expertise in the development of early stage biotech companies. As CEO of Biokine Therapeutics from (2000 -2005) he oversaw the company’s growth from an incubator company to receiving institutional investment and indeed licensing its first product to a European public biotechnology company. Following this, he became COO at CellGuide Ltd. Prior to moving to Israel, he was a management consultant with Datamonitor Strategic Consultants in London and New York. He has a law degree from Cambridge University, UK.

Ahmed Alimi C.P.A.
Chairman of the BOD

Mr. Ahmed Alimi is a chartered accountant by profession. He was the chief financial officer of the tourism division of the IDB Group. In recent years he is both an entrepreneur and investor involved in several life science ventures.

Riva Kovjazin, M.D
Senior scientist

Dr. Riva Kovjazin is an expert in the field of immunology with over 25 years of experience in cellular immunology. She obtained her degree in medicine from the School of Medicine, University of Perm, Russia and specialized in the advanced study of immunology and epidemiology of conventional infectious diseases at the Rostov Research Institute, Rostovdon, Russia. In addition, she was a project leader at the Center for clinical immunology, University of Medicine, Moscow, Russia where she studied the Clinical immunology and diagnosis aspects of HIV. From 1997 until 2007, Dr Kovjazin held various positions at XTL Biopharmaceuticals.


back to top